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Background
The National Institute for Health and Care Excellence (NICE) 
is responsible for producing technology appraisals and evi-
dence-based guidelines for health and social care, including 
public health, in England. The Wanless Report1 stated that “to 
achieve the objective of allocating funding more eficiently 
between health care and public health, it is vital that... analytic[al] 
methods are used”. NICE’s Centre for Public Health Excellence 
(CPH) was founded in 2005 to be responsible for producing the 
public health guidance, relating to “preventing disease, 
prolonging life and promoting health and eficiency”2.
After a NICE internal reorganisation in 2015, standalone direc-
torates were merged, making deinitions of public health 
appraisals less demarcated from other topics areas. Reference 
cases and other methods were harmonised across NICE in all 
guidance producing areas. Many of the unique aspects relating 
to public health were incorporated into the uniied methods used 
by NICE, and CPH staff redirected to the broader ‘Centre for 
Guidelines’ (CfG). Due to these changes, it was decided to limit 
the range of guidance topics in the review up until December 
of 2014, when the inal guidance topic under the CPH banner was 
published.
In practice it is challenging to adequately understand, quantify and 
model the multiple effects of many public health interventions3. 
Certain interventions cannot in practice be investigated 
directly due the methodological challenges speciic to public 
health; these include the attribution of effects to interventions, 
measuring and valuing outcomes, identiication of intersectoral 
costs/consequences, and how best to incorporate equity issues4,5. 
Economic modelling can in principle address many of these 
issues, providing estimates of effect and quantifying the uncer-
tainty related to these.
CPH guidance took into account the cost-effectiveness of the 
intervention, the likely impact of its provision on societal equity, 
and other concerns6 as part of the relevant committee’s delib-
erations. Final decisions on public health guidance require 
human judgement, regardless of the reference case and other 
frameworks used to structure them, which are “informed by sci-
ence but nevertheless judgements”6. Aside from the challenges 
of public health modelling more generally, understanding NICE 
decision making processes are complex and can be dificult 
to articulate and understand7. The full range of nuances and the 
complex nature of deliberations cannot necessarily be recorded 
accurately, leading potentially to a lack of clarity about how 
inal decisions are made, such as whether all relevant criteria 
have been given the appropriate consideration throughout, or 
how factors have been weighted implicitly. This is exacerbated 
by the fact that originally NICE committees were inaccessi-
ble to public viewing. One stage of the directorate’s decision-
making process at which all issues under analysis have been 
stated explicitly was during the economic modelling process.
For this reason, the objective of this paper was to complete a review 
of all economic modelling conducted in the CPH over the period 
of March 2006 to December 2014, in order to investigate the 
how the reference case was used in public health settings in 
practice, and in particular to assess 
•    the level of the heterogeneity in terms of the use of 
economic evaluation techniques,
•    perspectives on outcomes and
•    the measurement of non-health beneits.
The paper describes the variety of issues (and compromises) 
that have been considered in establishing the cost-effectiveness 
of various approaches as part of the guidance process. These 
relect the broad scope of public health settings and the wide 
range of costs and beneits at a population level outside of health. 
Each topic is unique, requiring its own criteria, choices as to the 
most appropriate economic appraisal technique(s) to be used 
and general lexibility, regardless of the oficial line speciied in 
the reference case, shown in Table 1.
The public health reference case gradually changed since the 
CPH’s foundation in 20058; it had initially been based heavily 
upon the reference case of the health technologies directorate. The 
CPH’s discount rate, for example, was reduced in 20129 to 1.5% 
to relect the long term nature of many public health interven-
tions (and because other directorates had begun to reduce the 
rate similarly), before being raised again in 2014. Further eco-
nomic evaluations are now also permitted than were initially the 
case. Other elements of the reference case have not changed 
over this time; for example, QALYs remain the sole recom-
mended measure of health effects and explicit equity weighting is 
not permitted – though these issues have too been subject to 
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occasional criticism10. The CPH had a speciic responsibility to 
consider the equity of outcomes alongside cost-effectiveness 
concerns11, and it was known the use of a purely CUA approach 
would fail to address equity or distribution issues directly12. 
Equity was not considered explicitly until the 2014 update to 
its methods manual13, and not incorporated into modelling; it 
was to be only considered later in the decision process.
When is modelling required?
The approaches used for economic evaluation in the CPH, as 
elsewhere in NICE, compared the costs of interventions under 
consideration with their expected beneits, making explicit how 
effectively they meet the directorate’s objectives. While there 
are differing approaches to quantifying the beneits and costs 
depending on the economic evaluation technique used, the CPH 
deined their aim broadly as “the promotion of good health and 
the prevention of ill health”, taking an “inclusive” perspective8. 
Over the long term, this quantiication should reduce the 
potential for inconsistent prioritisation and the opportunity costs 
associated with this, and lead to the “conscientious, explicit 
and judicious use of current best evidence in making deci-
sions about the care of individual patients”14. Evidence of the 
effectiveness of certain interventions is not always available and 
it is not always possible in practice to capture the full range of 
non-health population impacts into the model, and potentially 
hence into the broader decision process.
Table 1. National Institute for Health and Care Excellence (NICE)’s 2014 reference case for 
“interventions with health and non-health outcomes in public sector and other settings”. 
Prior to 2014, directorates (including the CPH) published their own standalone reference cases. 
QALY - Quality adjusted life year.
Defining the decision problem The scope developed by NICE
Comparator Interventions routinely used in the public sector, including 
those regarded as best practice
Perspective on costs •   Public sector – often reducing to local government 
•   Societal perspective (where appropriate) 
•   Other (where appropriate); for example, employer
Perspective on outcomes All health effects on individuals. For local government and 
other settings, non-health beneits may also be included
Type of economic evaluation •   Cost–utility analysis 
•   Cost-effectiveness analysis 
•   Cost–consequences analysis 
•   Cost–beneit analysis 
•   Cost-minimisation analysis
Synthesis of evidence on 
outcomes
Based on a systematic review
Time horizon Long enough to relect all important differences in costs or 
outcomes between the interventions being compared
Measure of health effects QALYs: the EQ-5D is the preferred measure of health-
related quality of life in adults
Measure of non-health benefits Where appropriate, to be decided on a case-by-case basis
Source of data for 
measurement of health-related 
quality of life (HRQoL)
Reported directly by people using service and/or carers
Source of preference data for 
valuation of changes in HRQoL
Representative sample of the UK population
Discount rate •   The same annual rate for both costs and health effects 
(currently 3.5%) 
•   Sensitivity analyses using rates of 1.5% for both costs 
and health effects may be presented alongside the 
reference-case analysis 
•   In certain cases, cost-effectiveness analyses are very 
sensitive to the discount rate used. In this circumstance, 
analyses that use a non-reference-case discount rate for 
costs and outcomes may be considered
Equity weighting A QALY has the same weight regardless of the other 
characteristics of the people receiving the health beneit
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The available evidence in public health tends to be from a broader 
range of settings and hence is sometimes shallower than in 
pharmacoeconomic studies, at least in terms of the hierarchy of 
evidence. These hierarchies follow a standardised ranking from 
randomised control trials to expert evidence, and are based upon 
the increasing probability of bias being introduced15. But they 
are not necessarily appropriate for use in public health settings3. 
The length of the causal chains for these interventions requires 
assumptions and judgements to be used, which must be tested 
through modelling and deliberation as the “principle of the 
accumulation of results of trials does not sit well with model 
and theory based sciences”3.
Similarly, expert judgement, deliberation and experience remain 
vital to decision-making within NICE. There is wide variation 
in this – the initial evidence review carried out for a topic may 
ind overwhelming evidence of effectiveness or cost-effectiveness, 
or in other cases effectively no such evidence. Economic mod-
elling is used in the area in between these extremes to better 
inform decision-makers, where further insight is required to 
interpret the evidence available. Where it is already clear in 
advance that the intervention would be cost saving or where it is 
obvious the costs are relatively small compared to the expected 
health gains, modelling is not necessary9.
How is modelling used?
Interpreting and deciding which evidence is most relevant to 
the model requires a pragmatic approach, utilising simplify-
ing assumptions. As with any scientiic setting, the model can 
therefore offer only an approximation. The model makes 
explicit the logical implications of the data available, making it 
easier for decision-makers to draw rational conclusions given the 
uncertainty associated with each potential course of action. In 
many cases ballpark igures will provide a strong indication of 
whether or not the intervention is likely to prove cost-effective. 
Many interventions in public health are extremely so; about 
15% of those investigated were shown to be cost saving and 
89% were below the usual NICE Incremental cost-effectiveness 
ratio (ICER) threshold of £30,00016. Probabilistic and sensitivity 
analyses can be used to further indicate the robustness of a model’s 
conclusions.
These assumptions and decisions are an inevitable part of the 
process and “economic modelling requires judgements to be 
made by both modellers and decision-makers”6. There are sev-
eral stages to this process. NICE usually tenders the evidence 
review and modelling processes to experts in academia, but 
CPH staff would liaise throughout to ensure that the methods used 
were in line with NICE’s requirements. The model must be req-
uisite – parsimonious but good enough to do the job17 – requir-
ing appropriate balancing between the aims, costs and effects 
of the interventions under review. Modellers, in collaboration 
with topic appraisal committees, must also make decisions as to 
where insuficient data are available to investigate certain inter-
ventions further. The study into Workplace interventions to pro-
mote smoking cessation (PH5)18, for example, was initially also 
intended to investigate mass media interventions, but the previ-
ously completed literature review found no relevant evidence of 
effect; it was therefore not pursued further in the modelling stage. 
As well as the use of the reference case, the 2012 CPH 
methods manual9 stated that modellers must ensure that: 
•    the most important questions or intervention areas 
are selected for economic analysis
•    the overall modelling approach is appropriate
•    important health effects and resource costs are all 
included
•    effects and outcomes not related to health are included 
(if they are material for the sector whose perspective is 
being used, usually the public sector, local government 
or the NHS.
•    best available effectiveness, epidemiological and 
resource evidence is used
•    model assumptions are plausible
•    uncertainties are fully explored and systematically 
addressed
•    results are interpreted appropriately and any limitations 
are acknowledged.
In some cases, de novo models are required, though on many 
occasions it is possible to base them upon previous work. 
Because over time the guidance on speciic topics is revised, 
previous models may be recycled, reducing the work required 
and easing comparisons between conclusions. There is also 
a limited number of themes explored in practice, and several 
tobacco related topics, for example, used a similar simulation-
based model indicating the probability of acquiring a number of 
smoking related conditions (or death) as simulated individu-
als aged (such as PH518, PH1019, PH1420). Similarly guidance on 
physical activity reused updated versions of a model incorporat-
ing the risk of coronary heart disease, stroke and type 2 diabetes 
mellitus (e.g. PH4421, PH5422). This allowed not just for com-
parisons between the effectiveness of interventions versus ‘doing 
nothing’, but also between topics. Other models are based upon 
or incorporate pre-existing work previously completed externally 
to NICE. Economic modelling may also solely focus on a spe-
ciic part of the guidance or investigate a sub-population of those 
to whom the broader guidance will apply.
Model perspectives and economic evaluation techniques
The CPH’s reference case, the set of standard approaches to be 
used in economic modelling and broader decision-making, was 
intended to be lexible where necessary on a case-by-case basis. 
This standard approach recommended a public sector perspec-
tive, to take account of the costs and beneits of each intervention9. 
The 2014 methods manual13 formally allowed for discretion on 
the perspective used across all NICE directorates for the irst 
time, varying according to the nature of the problem. Previously 
a public sector perspective was largely conined to public health 
settings. An NHS and Personal Social Services (PSS) speciic 
perspective is used where costs and beneits are largely related 
to health alone. This has also previously been used in many 
cases in public health and is the standard for drug and tech-
nology appraisals in NICE. Where these criteria largely fall 
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upon local authorities, a local government perspective can simi-
larly be used. However, in practice which perspective is used 
can be something of a moot point. In many cases models claim-
ing to use a public sector perspective used only healthcare costs 
(e.g. PH3223); in others, no perspective has been explicitly stated. 
Other perspectives are also possible, such as the employer ben-
eit for workplace interventions (PH518) or a societal perspec-
tive for example in cases of domestic violence (PH5024). These 
were codiied in the reference case for the irst time in the 2012 
guidance9, but had nonetheless previously been used. The most 
common economic evaluation techniques used in the CPH were 
Cost-effectiveness analysis (CEA), Cost-utility analysis (CUA), 
Cost-benefit analysis (CBA) and Cost-consequence analysis 
(CCA); for deinitions of these techniques see Drummond et al.25.
Economic modelling is informed by a prior evidence review, 
specifying the range of relevant interventions that have been used 
in the area in the past, the nature and strength of studies inves-
tigating them, and their effectiveness, costs and applicability 
to a UK context. Where no previous study has directly meas-
ured the outcomes under investigation, economic modelling can 
be used to compute estimates of these outcomes, using param-
eters populated based upon results derived from the literature 
discovered as part the evidence review. In cases where it is not 
appropriate or possible to further model results, generic discus-
sion pieces may still be written to discuss how an economic model 
would be used if such a thing were possible, and to indicate the 
magnitude, ‘wheres’ and ‘hows’ of the underlying uncertainty 
that make more formal modelling impossible.
Where possible, the costs of an intervention could be assessed 
based on the information available in the literature described 
in the evidence review. This typically included the costs of any 
device or pharmaceutical required, staff time, monitoring and 
maintenance costs, treating adverse events, rent and so on. Pub-
lic health also throws up more unusual consequences; the costs 
found in the review also included, for example: decreased tax 
revenues (PH4126); the impact of having to pay for extra years 
of health care (PH2327 - though these were more than out-
weighed by the decrease in costs treating the illnesses associated 
with smoking); and issues relating to injuries occurring as a side 
effect of the intervention (PH4421). The impact upon individu-
als volunteering to give up their time may be highlighted (PH928), 
though this cannot be fully incorporated into CUA as costs 
to carers and non-patients have in practice been considered outside 
the scope of NICE’s reference case.
Final decisions rest with the relevant committee for the topic, 
titled “Public Health Advisory Committees” (PHACs). Prior to 
the 2012 public health methods manual9, there were two dif-
ferent types of committees in their place. The Public Health 
Intervention Advisory Committee (PHIAC) was a standing 
multi-disciplinary panel which could look at clear, well deined 
public health topics, such as “Prevention of sexually transmitted 
infections and under 18 conceptions”29 and “School-based inter-
ventions on alcohol”30. Programme Development Groups (PDGs) 
were assembled on a topic-by-topic basis, to create guidance in 
broader, more complicated or less clearly deined areas, such as 
“Behaviour change”31 or “Community engagement”28.
Equity in economic modelling
Issues relating to equity are also not currently formally consid-
ered as part of the economic modelling stage, though of course 
they remain a fundamental part of the broader guidance devel-
opment process. In a similar manner to the impact of volun-
teerism, this does not mean that such issues are irrelevant to 
the modelling stage. The Tuberculosis: hard-to-reach groups 
(PH3732) guidance explained how out-of-pocket expenses 
– again relevant to private individuals rather than to the public 
sector perspective, which was used in this model – are likely to 
have a disproportionate effect on homeless populations. As such, 
they may be relevant not solely to ethical issues around access 
for these groups, but also in the practical terms of the likely 
real-life effectiveness of the intervention (assuming that home-
less populations will have signiicantly lower uptake than might 
otherwise be expected as a result). The committee could then 
take this into account during the later stages of formalising 
recommendations. Equally, though the modelling itself may 
not deal with equity head on, at times the topic itself may obvi-
ously relate to improving health outcomes for speciic vulnerable 
groups. And during several topics, public sector (and societal) 
perspectives may bring into consideration areas outside of 
healthcare where outcomes appear to be heavily inluenced by 
socioeconomic and other factors.
Interventions may also increase inequality in the short term 
if higher social status groups are likely to beneit from irst 
mover advantage. Having worked on developing the guidance 
on Walking and Cycling (PH4126), there was a concern that 
such an issue may arise (at least temporarily), though it was 
hoped that in the longer term there would be increased uptake 
amongst all groups. A similar concern was expressed in pub-
lished guidance on Physical activity and the environment (PH833). 
It is tempting to draw a comparison with the Kuznets curve34, 
which implied that as a nation’s economy develops inequality 
will widen for a time before ultimately reducing once a certain 
overall level is attained; a similar phenomenon relating to 
health inequalities may exist in certain public health settings.
At times decisions in the CPH could even hinge on seemingly 
inconsequential differences in interpretation of the scope at 
present and such subtleties may prove dificult to represent in 
models. The scopes may themselves change, via gradual, subtle 
reinterpretation in light of the facts as they emerge. The facts 
used are not always self-evident and require judgement and an 
understanding of the causal chains of effect35. With a new gov-
ernment, wholesale changes in scope are also possible. PHACs 
always needed to interpret some issues in an ad hoc manner 
as they arose – using their experience and judgement as part 
of this – though recommendations had to be formulated carefully.
An example framework from start to inish for developing the 
economic model, taken from PH4126, is shown in Figure 1, 
displaying the variety of stages required from deining to whom 
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the modelling stage should apply through to quantifying the 
cost-effectiveness in monetary units.
Methods
All economic modelling reports on public health topics, published 
by NICE between March 2006 and December 2014 were eligi-
ble for inclusion in this review. These are published on NICE’s 
“Guidance and advice list” webpage. Each guidance topic has its 
own webpage listed there, containing an ‘Evidence’ section. This 
lists relevant reports offering supporting evidence on which 
the subsequent decisions are based. The reports available vary 
from topic to topic, but typically contain an effectiveness/cost-
effectiveness literature review, an economic modelling report 
and (if a suficiently long period has passed since the guidance 
was issued) a report reviewing whether to update the guidance. 
On occasions, further reports are included such as ieldwork, 
qualitative approaches or case studies. Reports do not have a 
standardised nomenclature and occasionally the modelling 
report is incorporated into the literature review.
For this review, all reports which are described as relating to 
economic modelling for each piece of guidance have been inves-
tigated. Where a topic’s guidance webpage has no listed “eco-
nomic modelling” report, all reports labelled under evidence, 
effectiveness and cost-effectiveness were reviewed to ensure that 
economic models that were instead listed there were included 
in this review. For topics that instead reviewed a series of case 
studies to illustrate the potential cost-effectiveness of approaches 
- such as Strategies to prevent unintentional injuries among 
under-15s (PH29) – these case reports too were investigated 
and described. This process was carried out primarily by BR, 
with recourse to the co-authors where necessary.
Figure 1. Example prospective modelling framework, as used in Public Health (PH)4125.
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There was no simple one-to-one relationship between topics 
and modelling reports. While some guidance did not require any 
modelling approaches, others used multiple models in the same 
report, or across multiple reports. Sometimes this was to relect 
topics where different perspectives are possible, such as ini-
tially using an NHS and PSS perspective before investigating 
the effect of considering further public sector or societal issues. 
On occasions where a topic is broadly deined, a wide variety of 
very different interventions may it under the deinition and 
in such cases a smattering of these may be used as case studies.
Results
In total 56 Public Heath guideline reports were published 
between March 2006 and December 2014 by NICE, and follow-
ing screening all were included in the review (see Figure 2). 13 
of these used no economic modelling. Of the remainder, 30 of the 
43 used CUA alone. Others typically used CUA alongside 
other approaches: 3 used CBA, 3 CCA, 2 Net Financial Ben-
eit (NFB) and 1 arguably used both CBA and CCA. One used 
an approach that could be equally described as CBA or CUA 
(described later). Many used more than one model, and in 
total 61 models were published.
Unsurprisingly, the primary criterion used to quantify the ben-
eits of interventions has been health, generally represented by 
QALYs, though there have been both exceptions and additions 
to this. For example, the “contraceptive services with a focus on 
young people up to the age of 25” [PH51] economic model uses 
a series of CEAs – such as reduction in the rate of ectopic preg-
nancies – which were not subsequently translated into QALY 
gains, and “promoting physical activity in the workplace” 
[PH13] guidance (which was aimed at employers) described 
the potential reduction in absenteeism rather than health 
outcomes.
Figure 2. Economic modelling techniques used in NICE public health guidance published between March 2006 and 31 December 
2014. CBA: Cost-beneit analysis, CCA: Cost-consequence analysis, CEA: Cost-effectiveness analysis, CUA: Cost-utility analysis, 
NFB - Net Financial Beneit.
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ICERs have been calculated using a variety of approaches, par-
ticularly Markov modelling techniques such as state transition 
modelling and cohort simulation studies. At times, the number 
of deaths or cases averted is shown (e.g. PH4126) in addition 
to the QALY measurements; in principle, such an approach 
could be expanded upon more formally in a CCA.
For simple cases using CUA, the QALYs lost to mortality and 
morbidity are calculated, such as from fatal and non-fatal myo-
cardial infarctions (PH631). Where the data are available, and 
a broader perspective is required, the reduction in quality of 
life associated with non-health causes may also be incorporated. 
However, in many cases, such research was not previously car-
ried out and cannot therefore be reliably quantiied, meaning 
such outcomes were excluded from the model.
In Interventions to reduce substance misuse among vulner-
able young people (PH436) for example, the reduction in QALYs 
associated with robbery was included because a previous study 
had estimated this effect. But the effects of other crimes listed 
in the initial model were excluded as no comparable studies 
had been carried out (and even though it is relatively clear that 
these would similarly have had a negative effect on people’s lives 
and health). The effects of unemployment were excluded from 
the inal model for the same reason. Similarly, guidance on Man-
aging overweight and obesity among children and young peo-
ple: lifestyle weight management services (PH4737) explained 
that while related bullying and subsequent mental health issues 
are clearly relevant, there have been no studies indicating their 
health-related quality of life impact. Because these may well 
be implicitly included in prior studies, they were excluded 
as to include them would risk double counting their effects.
Such exclusions may mean that the full range of beneits are not 
taken into account in the model, potentially increasing the appar-
ent ICER (assuming the full range of costs are included) and 
therefore making the intervention look less cost-effective 
than it might otherwise.
To a certain extent it may be possible to include such data in 
other ways, such as using a CCA. In Physical activity: brief 
advice for adults in primary care (PH4421), for example, the CUA 
model included the QALY impact of increased physical activity 
on reducing coronary heart disease, strokes and type 2 diabetes, 
whereas the CCA approach incorporated these factors along-
side the improvement in outcomes in mental health, cancer 
and a broader range of health effects, as well as further beneits 
from reduced absenteeism in work.
Smoking cessation in secondary care: acute, maternity and men-
tal health services (PH4838) extended this approach further, ini-
tially carrying out a CUA using an NHS and PSS perspective 
and subsequently building upon this. In the original model, a 
Markov simulation was used, incorporating reduced coronary 
heart disease, chronic obstructive pulmonary disease, lung can-
cer, myocardial infarctions and stroke. Because the effective-
ness of approaches may vary depending on the setting in which 
they were employed, models were tested for a variety of case-
study type scenarios such as maternal and neonatal health issues, 
mental health and preoperative settings. Further inputs to each 
case study speciic model could then be more relevant and reli-
able, and an initial ICER calculated. Subsequent cost savings from 
offsetting future costs of treating smoking related diseases were 
next included and a revised “total ICER” calculated. A societal 
perspective was then used, by incorporating the savings attrib-
utable to increased productivity from employees. Though 
referred to in the text of the report, the corresponding ICERs using 
this approach appear to have been removed from the relevant 
tables and net inancial savings to employers portrayed instead.
The economic modelling methodologies used in each of the 
56 public health guidance topics carried out up to the end of 
2014 are available as extended data39. Where a single model is 
used, even for multiple interventions or across multiple reports, 
this is listed only once except in the case of PH1240, where two 
wholly different CUA models were used. Non-CUA approaches 
are described separately. At times multiple perspectives were 
also used as part of the modelling process and at others it 
was dificult to ascertain which perspective was actually used. 
Where a public sector or societal perspective has been claimed 
but only health related costs and beneits included, these have 
been listed as they were described in the report. In others there 
was no clear perspective speciied and only healthcare crite-
ria were described, and these have been listed as having an 
NHS and PSS perspective.
In total, an NHS and PSS perspective was the most com-
mon perspective used, on 30 occasions (though PSS generally 
appears to have had little or no impact). A public sector approach 
was used on only 15 occasions, despite this being nominally 
prescribed by the reference case. A societal approach was 
used on 11 occasions and an employer perspective 4 times. 
The 13 topics that did not include a model naturally used no 
perspective.
Of the studies that used CBA or CCA before the 2012 guidance 
elevated their role, all except one are concerned with the related 
areas of travel or physical activity. As CBA is widely used in 
transport planning, this result is not surprising. The remaining 
study, relating to preventing harmful drinking (PH2441), argu-
ably contains both a pseudo-CCA approach – listing a range of 
likely outcomes of each potential intervention in their natural 
units – and a “valuation of harms analysis” which bears a 
striking resemblance to CBA, which is further discussed later.
Workplace interventions have in the past used net inancial ben-
eit for an employer’s perspective arising from increased pro-
ductivity and reduced absenteeism (PH518, PH1942). CBA and 
CCA as a rule use societal approaches, further broadening the 
scope by which to judge interventions, allowing for the inclu-
sion of issues such as environmental effects and reduced trafic 
congestion (PH4126) reduced travel time and increased comfort 
(PH833), estimates of impact upon the economy (PH2441) and 
woollier concepts around “human costs” (PH3143).
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There are a series of judgements to be made regarding what 
is relevant in cost-effectiveness modelling, though broadly 
speaking the NICE protocol is to include all relevant factors6, 
which can be subject to considerable uncertainty.
Because the assumptions used in building the model may not 
hold in practice, modellers need to be upfront about potential 
weaknesses and to employ sensitivity analyses to ensure indings 
are robust. Due to the complex nature of public health interven-
tions, there are unique challenges in applying these approaches 
to this sector and judgement will naturally play a key role in 
interpreting the model’s indings. One topic (PH3944 – which 
contained the memorable proviso that “even the uncertainty is 
uncertain”) attempted to use a Markov model to estimate the 
prevalence and survival rate of various conditions arising from use 
of smokeless tobacco amongst South Asian communities. Due 
to a lack of data, particularly on the costs of interventions, the 
predicted cost-effectiveness of the intervention was felt to be 
extremely uncertain. As such, the authors aimed only to high-
light this issue and encourage decision-makers to exercise 
their judgement in making conclusions from the report’s indings.
“Naturally, one has to weigh these igures with one’s own assess-
ments of where the base line estimates have been too optimis-
tic or too conservative. The analysis presented here offers a 
starting point to guide one’s assessment. The data limitations are 
too severe to offer anything else.”44
The PHAC committee and modellers can collaborate to decide 
whether modelling is required at all; it can be skipped if the evi-
dence review has already clariied the likely interventions’ effects. 
Such issues can be considered formally using the Grading of 
Recommendations Assessment, Development and Evaluation 
(GRADE) system9,45. This facilitates the evaluation of stud-
ies across ive criteria: the risk of bias within studies; the direct-
ness of evidence; consistency of evidence; the precision of the 
estimated effects (relative to decision-making); and publication 
bias. These issues must be considered for both the intervention 
and the comparator. On two occasions, principles of economic 
modelling were employed to generate whatever insights were 
possible, though it was known in advance that full implemen-
tation of a model would be unsuitable due to lack of suitable 
comparators: 
•    Not only were very few studies available for the 
guidance on the costs and beneits of community 
engagement programmes (PH928), but deining precisely 
what constitutes such an intervention was deemed 
effectively impossible. These dificulties were tied up 
with issues regarding how to quantify concepts felt to 
be universal goods, such as democracy, empowerment 
and social capital.
•    The Obesity – working with local communities project 
(PH4246) employed economic modelling to investigate 
“partnership working to reduce obesity”. This 
attempted to describe the decision problem from 
a costs perspective, while maintaining that there 
exists no worthwhile comparator by which to judge 
cost-effectiveness and that such beneits would be too 
dificult to measure even if such a comparator could be 
found.
While CUA models applied to NHS and PSS settings are gen-
erally relatively simple to interpret, other approaches using a 
broader perspective or differing methodologies require more 
nuanced and careful consideration (and ultimately trade-offs). 
These topics and the criteria considered as part of the model-
ling are available as extended data39. Many contained non-health 
beneits (as classiied by the authors of this paper), posing 
further challenges to decision-makers It is not immediately 
clear how best to incorporate these. The complex negotiations 
around inter-sectoral effects are well beyond the scope of this 
paper. But it is worth reiterating that choosing to ignore such 
non-health factors is in itself a decision, and a rather nihilistic 
one at that.
A wide range of non-health beneits was found in the review 
of CPH guidance. Where a public sector perspective was 
used, cost savings to government departments aside from the 
Department of Health become relevant to the decision-making 
process. Reduced productivity, normally measured through absen-
teeism or presenteeism, occurs on 12 occasions (e.g. PH4421, 
PH4838, PH5024). Criminal justice service costs arise on 10 occa-
sions, incorporating the combined costs of arrest, custody, court 
appearances and prison (PH436), police costs in implementing 
laws (PH2947) and the impact of conviction on future wages 
(PH4048). While costs on individuals are outside of the reference 
case, reduced income implies reduced tax revenue for the govern-
ment in the future, and becomes relevant in this perspective. A 
similar approach is employed for educational attainment, which 
arose on 4 occasions (PH730, PH1239, PH2049, PH2850). Knock-
on effects on spending are also included, such as reduced costs 
of providing unemployment beneits (PH2441) and drug treatment 
(PH436). Emotional wellbeing, broadly deined, was incorporated 
into the decision framework on 5 occasions (PH833, PH928, 
PH3143, PH4737, PH5024).
Discussion
Comparison to previous studies
Weatherly et al.4 (also described in an associated report by 
Drummond et al.51) reviewed 154 economic evaluations of public 
health interventions worldwide from 2000 to 2005 and found that 
32% used a health service perspective and 31% a self-described 
societal perspective (though this was felt to be an overestimate) 
and 48% of which related solely to health. 24% had no stated per-
spective, 3% used multiple perspectives and the remainder related 
to local healthcare provider, government or patient. In contrast 
to the CPH guidance, the Weatherly paper found CCA was 
used in a relatively high 37% of studies, while 27% used CUA 
(whether based upon QALYs or the related Disability adjusted 
life years). A further 36% used CEA (excluding CUA), such 
as units of weight lost, alongside their cost information. CUA 
and CEA are recorded separately. 4 reports (3%) claimed to use 
CBA but these were upon further investigation re-categorised 
as CCA or CUA. Though it is worth reiterating that evalua-
tions described in the Weatherly paper were not conined to UK 
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settings (61% were from the US, 15% UK, 6% Canada and 4% 
others) – and are not directly comparable to NICE economic 
modelling – issues relating to costs to the voluntary sector and 
to private citizens were felt by the authors to merit further atten-
tion. Equity considerations, however, were rarely described in the 
literature and never addressed formally (and the authors argued 
that this implies that QALYs were simply summed directly for 
the studies using CUA). It is argued that these should be better 
highlighted, and opportunity costs of implementing more 
equitable interventions made transparent.
McDaid and Needles’ report52 featured 1700 studies from the 
mid-1960s to mid-2000s. 49% of studies were based in the 
US, 13% in the UK, 5% Canada, 4% Australia and 4% from 
the Netherlands. Intervention settings, rather than perspectives, 
are reported. 22% took place in workplace settings (overwhelm-
ingly in the US). 8% took place in schools or colleges of higher 
education. Others (though no speciic proportions are given) were 
funded by the state, social health insurance or by individuals; 
understandably, these tended to have less direct impact on pro-
ductivity than the interventions that employers had chosen to 
provide. 57% of studies used CEA, 21% CCA, 13% used CUA, 
and the remainder used CBA (5%), econometric techniques (3%) 
or cost-minimisation approaches (1%). The authors emphasise 
the critical importance of context in understanding the inlu-
ences of uptake and successful implementation of techniques, 
and argue that novel policy level approaches to funding are 
needed to ensure that non-health impacts of interventions are 
given adequate consideration. These will likely require further 
government investment given the diffuse nature of the beneits that 
accrue from interventions of this nature.
Though not strictly public health, a literature review describing 
the economic evaluation techniques used in social care was pub-
lished in 200253. Mental health and public health were the two 
most common topics that used such techniques, totalling about 
two thirds of all reports. Many related to multiple issues at the 
same time, and this complexity presents further similarities 
with the attempts at applying such evaluations in public health. 
In total, 131 reports are reported, taking place over 5 years. The 
perspective used was not reported (though elsewhere in the report, 
the importance of a societal approach is emphasised). 65% of 
studies used CCA, 18% CEA, 5% CBA and 6% each for 
cost-minimisation analysis and cost-saving analysis. 72% of 
studies had taken place in the US, 15% UK and 13% other.
Nonetheless, a Cochrane review on public health evidence in 
practice54 found that the indings of studies to inform local pub-
lic health decision-making are rarely published (and that they 
rarely meet the standards required for subsequent system-
atic reviews anyway). This may mean that the reviews listed in 
this section do not relect the full range of research undertaken 
applying economic evaluation techniques in public health.
Potential implications
Economics is ultimately about the studying of decisions, the 
incentives behind them and their consequences55; health econom-
ics relate to these choices in the context of the resources available 
in health generally. Public health economics can be deined as 
the “study of the economic role of government in public health, 
particularly, but not exclusively, in supplying public goods 
and addressing externalities”56. The broader effects of such 
interventions, taking into account a range of other factors, 
mean that such decision-making is much more complex than 
some other settings in health. This paper has already highlighted 
the range of factors considered in NICE’s public health economic 
modelling. Complicated decisions merit that models of some 
sort are used to structure the information available to better 
inform decisions makers, who may otherwise make unnecessary 
mistakes57.
Ultimately, nearly all economic models used in the CPH trans-
lated the indings from relevant papers into gains in utility in 
order to facilitate a CUA approach for NICE guidance. However, 
such translation runs the risk of oversimpliication5. While 
it is accepted that potential costs and beneits should be 
identiied and highlighted in the limitations section or elsewhere, 
even where they cannot be measured - Sheill argued that those 
issues that are not measured, may ultimately be cast to one side 
if they cannot be incorporated into calculations58. This could 
in principle be remedied somewhat if these issues were listed 
explicitly for later deliberations, but it is well established that 
human intuition is systematically subject to predictable biases 
for complex problems59 of this nature. The use of a model 
can counter this, though in such a scenario all factors that are 
considered relevant would need to be measured, or else incor-
porated in an innovative way58. There may therefore be a case 
for using these CCAs and CEAs directly in future in certain 
circumstances, or potentially extending these to multiple cri-
teria decision analysis (MCDA) approaches. These techniques 
potentially hold a number of advantages for prioritisation in 
policy making settings60, as well as well-documented possible 
stumbling blocks61.
The use of different methodologies may not lead to as many 
changes as one might think, as there is a large amount of overlap 
and ambiguity between approaches at times. CBA and net inan-
cial beneit appear to be for all intents and purposes equivalent 
approaches. Both apply monetary valuations to costs and ben-
eits arising from implementing the approach in order to arrive at 
estimations of the net beneit arising from it. The main difference 
appears to be that net inancial beneit was used as the term of 
choice when an employer perspective was used. As such, it has 
been maintained in the tables above as initially described, but 
it is worth bearing this in mind.
CBA also has links to CEA (and ultimately CUA). Guidance on 
Contraceptive services with a focus on young people up to the 
age of 25 (PH5162) used a CBA approach which was built up 
upon the cost per negative outcome avoided (i.e. CEA) on a range 
of criteria, such as costs of maternity care, miscarriage, ectopic 
pregnancy and stillbirth, which had all previously been esti-
mated in prior NICE research. The model estimated probabili-
ties of each event occurring with and without the intervention. 
These could be combined formally (including the costs arising 
to future governments of beneit pay outs) to calculate the cost 
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savings attributed to the intervention. The approach was found to 
be dominant. It would therefore similarly be dominant for CUA, 
regardless of any conceivable threshold used (assuming the 
same costs were taken into account in both cases). A similar 
approach was used for Domestic violence and abuse: how health 
services, social care and the organisations they work with can 
respond effectively (PH5024), in which all conceivable costs 
and beneits were calculated on a societal level and the inter-
ventions modelled were found to be dominant. While it was 
described as a CUA, in such a scenario there is no clear line 
between CBA and CUA.
Such an approach nonetheless poses challenges. CUA has usu-
ally been used as part of an NHS and PSS perspective, and 
extending it to a public sector or societal perspective makes 
it unclear how to draw a threshold when non-health expendi-
ture becomes involved. This can (rightly or wrongly) be 
ignored in the particular cases of PH5024 and PH5162, where the 
interventions were found to be dominant. But if this was not 
found to be the case, it is not clear if the normally used thresh-
old would be applicable. Would it be acceptable, for example, to 
approve an intervention with an ICER of £35,000, but where there 
are broader implications outside of healthcare? Such ques-
tions will need further revisiting in future if CBA does become 
more common in NICE’s modelling. These issues have been 
discussed elsewhere4,63,64. While no consensus has as yet emerged, 
the unambiguous cost-effectiveness of most of NICE’s public 
health interventions16,65 make the issue somewhat moot for now.
There is also the risk that in giving modellers free rein over 
which consequences of the intervention to include when using 
a societal perspective, they may (unconsciously or otherwise) 
cherry-pick effects which will help their case in approving the 
guidance. Even if similar risks are possible using a healthcare per-
spective, there will be clearer borders and experience in terms of 
what is and is not relevant. In a societal approach, aspects relat-
ing to criminal justice, education, or even tourism or the arts 
could feasibly be included or excluded at the whim of model-
lers, and if the PHAC members fail to query the position then 
these factors will inluence all future decision-making. Even 
if the 2014 methods guidance allows other directorates to 
use such perspectives, if they are not widely adopted outside 
of public health it may make like-for-like comparisons of 
the cost-effectiveness of interventions more dificult between 
directorates.
On a more positive note, the ambiguity between CBA/CUA/
CEA (and potentially CCA) does offer potential advantages. 
Where there is evidence that an approach is effective but no 
evidence of its magnitude, in the past this has generally been 
omitted from modelling entirely. CCA could be used to meas-
ure the direction of such issues and checked for dominance or 
what-if analyses to investigate whether the required effective-
ness of interventions was plausible. PH5162 offers what appears 
to be an equivalent way of structuring the problem. It implicitly 
assumed that the intervention’s outcomes were better than the 
alternative (e.g. no ectopic pregnancy is better than an ectopic 
pregnancy), making intuitive sense, even though mortality 
estimates for these were zero and utility measurements for each 
were not available. Such an approach could be further extended 
where committees are willing to explain the logic of their assump-
tions, allowing formal quantitative approaches to be used in 
settings where they are not currently available.
The 2012 methods manual9 stated that CCA had previously been 
used ‘implicitly’ for trade-offs between cost-effectiveness and 
equity (and other concerns) at other stages of the guideline devel-
opment process, but could now to be adopted more formally. 
Even within the economic modelling stage, a type of pseudo-
CCA was used in “Alcohol-use disorders – preventing harmful 
drinking” (PH2441). The irst time it was used more formally 
was in PH4441. In the past, equity considerations have been con-
sidered out of scope according to the reference case. While other 
areas of the reference case have been considered lexible on a 
case-by-case basis, the change in emphasis underway may per-
mit equity trade-offs to be considered more explicitly as part of 
CCA modelling and that “the sets of consequences have been 
implicitly weighted should be recorded as openly, transparently 
and as accurately as possible” and “various tools are available to 
support this part of the process”9. Again, for a variety of reasons, 
MCDA techniques may be well placed to carry this out.
These equity concerns – which are in theory fundamentally 
important to public health decision-making – could also be given 
some formal weighting. Where equity factors are seen to inlu-
ence the results of the guidance this will likely lead to some 
controversy – but it is worth bearing in mind that such considera-
tions are already carried out without the help of a formal model 
and that opening such decisions up to some level of scrutiny 
seems entirely appropriate. If the equity concerns are seen to 
be too inluential and costly in terms of societal health, or vice 
versa, then the weighting on equity for future appraisals could 
be adjusted. At present the decisions of PHACs cannot be held 
to the same level of accountability in such circumstances.
On the other hand, even if a workable deinition of equity was 
speciied66, then assessing what weight is appropriate for equity is 
not immediately clear67. It is plausible that this might not be nec-
essary however; for example, MCDA could be used as part of a 
what-if style analysis. If, for example, an intervention would 
only be worth investing in if equity concerns made up 90% of 
the total decision, then this might provide a clear justiication to 
decision-makers for refusing to invest. Over time, a de facto 
threshold level may emerge through precedent and prior expe-
rience, though this step may not be necessary to improve 
decision-making processes.
Limitations and challenges
Similar to other studies that are reviews of previously published 
studies, our review suffers some limitations. These include limi-
tations of sample size, availability of data, type of data extrac-
tion and self-reporting. It was dificult to extract the data 
about economic modelling as there was no clear template for 
reporting PH studies and thus, all the documents had to be 
searched to extract the information about modelling. Whilst it 
is possible that some data could potentially be missed, we are 
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conident in our review process extracted all relevant informa-
tion. This review only extracted information at an overview 
level (i.e. type of economic evaluation methods) and involved 
qualitative synthesis. It would have been useful to extract detailed 
information (e.g. the results, whether the intervention was 
deemed cost-effective, other beneits considered beyond QALYs) 
and analyse the underlying relationships using quantitative 
techniques. The data extracted is based on the CPH authors’ inter-
pretation of the economic modelling, however, given the estab-
lished nature of this ield we are conident that our interpretation 
of the CPH reports are as the authors intended. Regarding the 
number of studies included, we have a reasonable sample size as 
our review included all the topics in CPH from inception to the 
end of  2014. It should be noted that the new methods manual 
that came into effect in 2015 (including even how public health 
topics are coded) and thus our review only included studies 
prior to the new methods manual. Future research on the dif-
ferences before and after the introduction of the new methods 
manual would be useful.
Conclusions
Of the 56 eligible guidance topics, 43 were found to have used 
economic modelling while 13 used no formal economic model. 
In total 61 economic models were published over the relevant 
period. Models were shown to vary considerably from each 
other, despite the reference case. Both health and non-health 
issues were regularly taken into account, the economic evalua-
tion methodology used varied from case to case, and the reference 
case was clearly applied lexibly - most obviously in the fact that 
its speciied public sector perspective is not the most common 
approach used.
Another interesting inding was that under certain circumstances, 
certain economic approaches are indistinguishable from each 
other and effectively equivalent. However, in other cases the 
same threshold is used regardless of the perspective and methodol-
ogy used, which may lead to inconsistent decision-making.
It seems an oversight that equity is not considered at the model-
ling stage – which is the one stage that uses formal quantita-
tive decision analytical techniques that are incorporated into 
the guidance process. It would be interesting if equity concerns, 
and the trade-offs and opportunity costs associated with them, 
could be formally compared. This could lead to more consist-
ency and would greatly improve the transparency of the proc-
ess. At present we have no way to look retrospectively at these 
issues, and we can only hope and trust that deliberations dealt with 
them even-handedly and comprehensively. Publishing a list 
of equity issues (or perhaps other factors) taken into account 
as part of deliberations subsequent to economic modelling for 
each topic could also allow retrospective quantitative analysis of 
such issues in future.
Upon its foundation, the CPH represented an ambitious attempt 
to impose economic evaluation methodologies on disparate pub-
lic health settings. As such there was no clear roadmap of how 
best to approach such issues, which instead needed to be worked 
out by trial and error. This is relected in both the changing 
reference case and in the related changes in the types of economic 
evaluations techniques used. As such, inconsistencies between 
guidance topics are understandable. But this combination of 
being both novel and clearly quite tricky to get right may in future 
merit the further investigation of formal techniques to address 
such issues. MCDA approaches could offer some beneits, in 
principle ensuring that decision making is more transparent 
and consistent between appraisals.
Data availability
Underlying data
All data underlying the results are available as part of the 
article and no additional source data are required.
Extended data
Figshare: Pub health economic modelling NICE appendices. 
docx. https://doi.org/10.6084/m9.igshare.12156063.v139
- Pub health economic modelling NICE appendices.docx 
(Word document containing the further tables) 
•    Appendix 1 - Economic modelling methodologies 
used in all previous CPH guidance
•    Appendix 2 – Health and non-health criteria 
considered for approaches that used perspectives outside 
of NHS and PSS
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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